Part II in the BHRT Workshop Series
EXPAND TREATMENT OPTIONS
Mastering the Protocols for Optimization of Hormone Therapy
March 18-20, 2022
September 23-25, 2022
Live Stream + In Person | Salt Lake City
Part II follows with advanced concepts and up-to-date research above and beyond Part I. This three-day seminar will keep you current on the appropriate skills needed to manage everyday problems. It will serve as a short refresher but will primarily be new and alternative therapies not explained in Part I. Alternatives to standard therapy are needed for complex and difficult cases. The field of age management medicine continues to grow at a rapid rate, making it difficult to stay abreast of all the changes that will be reviewed in this course which also undergoes yearly update. Included in Part II is an hour-long lecture that reviews the scientific literature giving credence for this type of practice of anti-aging medicine or simply preventive medicine. Over 200 peer-reviewed articles, the foundation for Dr. Rouzier’s advanced course, will be provided as a reference for the participant for those wishing to provide power point presentations to their medical staffs. This is the same lecture Dr. Rouzier gives to medical academies to inform physicians of the health benefits of age management therapies. Although Part I focused on the nuts and bolts of prescribing and monitoring hormones, Part II is much more complex and focuses more on literature reviews demonstrating longevity benefits of HRT, particularly as they pertain to cardiovascular and cancer protection. The following agenda better describes each section.
This course is offered as in-person and via live stream, choose your preference during the registration process. We will also post the recording each evening for that day. The recording will be available till Thursday of the week after the event to re-watch or catch anything you may have missed. It will NOT be available after this time.
Upon completion of this workshop, the healthcare professional will be able to:
- Identify important issues in the relationship between hormones and cancer: cause, provocation or protection?
- Outline problem-solving techniques for difficult cases presenting with multiple disease processes and the potential benefits of hormones.
- Discuss literature citing new indications, risks, benefits and complications of estrogen, progesterone and testosterone therapy.
- Determine advanced treatment modalities and dosing strategies for estrogen and progesterone, including new and specific approaches to these therapies.
- Describe important aspects of the WHI findings: identify the experts that refute this study, and other factors not included in the trials that would change the conclusions.
- Determine advanced treatment modalities, including new and specific approaches to HGH, thyroid and testosterone in age management and disease prevention.
- Discuss over 40 articles that demonstrate thyroid replacement does not cause osteoporosis, even in TSH suppressive doses.
- Identify various new therapies for erectile/sexual dysfunction in men and women.
- Evaluate the epidemiology of cardiovascular disease and diabetes and the various treatment strategies as they pertain to medication, diet, exercise, lifestyle change and nutritional supplements.
- Explore the role of omega 3 fatty acids, antioxidants, niacin, glucose, and their influence on insulin, inflammation, disease progression and atherosclerosis.
- Describe the strategies for using the new cardiovascular risk markers, inflammation markers, new lipid parameters and how to make sense of all the new lipid fractionation components.
- Identify rational approaches to vitamins and supplements with a review of the medical literature supporting their use in wellness as well as citing any harmful effects and interactions.
- Determine current screening methods and management strategies of the most common pre-menopausal hormone disorder, Polycystic Ovary Syndrome (PCOS) in addition to, implementing diagnostic and treatment strategies for PCOS.
- Apply diagnostic and treatment strategies for hirsutism and hair loss.
- Implement strategies for treating osteoporosis using hormone replacement therapy.
- Provide insightful and clinically meaningful cases to better help clinicians improve their practice and patient outcomes.
Neal Rouzier, MD
Dr. Neal Rouzier is a pioneer in the bio identical hormone replacement field, practicing almost since its inception in the early 1990’s. He has dedicated his life’s work to uncovering the medical literature that supports safe and effective protocols for unique and personalized patient care. He is the Director of the Preventive Medicine Clinics of the Desert, specializing in the medical management of aging and preventive care for men and women. He has treated more than 2,000 patients with natural hormone replacement therapy and is recognized as a renowned leader and expert in the field. Additionally, Dr. Rouzier is the author of Natural Hormone Replacement for Men and Women: How to Achieve Healthy Aging. He has over 16 years of experience as an educator and practicing physician, and 29 years of Emergency Medicine experience at Queen of the Valley Hospital in West Covina, CA.
8:00 – 10:00 a.m.
Making sense out of the many HRT studies, the critiques, and the rebuttals.
A commentary as to why estrogen is not harmful in most circumstances.
A critique of the WHI trial and a meta-analysis demonstrating opposite conclusions of the WHI. Putting the pieces together will make you an expert on all ifs, ands, or buts. It is the knowledge and command of this scientific literature (that your colleagues will never know) that makes you the expert. Estrogen replacement is so very complex and a full understanding of all the studies and data is necessary to prescribe and defend HRT. Having a command of the literature will enable you to explain when estrogen is indicated, which one, and why, the safety of estradiol and potential harm of CEE, the harm of not utilizing estrogen and estrogen depravation, and the harm of assuming and extrapolating the harm of CEE to E2.
10:00 – 10:15 a.m. – Break
10:15 – 12:15 p.m.
Review the hormone paradox and the myths and controversies of the oncogenic effects of hormones as to whether they are causative or protective against cancer. A literature review of HGH & testosterone in men will show benefits of protecting against cancer as opposed to the incorrect common opinion of testosterone causing cancer. As for women, estrogen and progesterone are also accused of causing cancer in spite of the literature support for the contrary. Studies will be reviewed that evaluate whether they cause cancer or protect against cancer and how optimization protects against cancer. Well review all the literature that proves MPA ≠ OMP. Finally, testosterone is second to progesterone in protecting against breast cancer. Can estrogen be safely used in cancer survivors? Over 40 studies prove it can and should be used. Not replacing hormones increases morbidity and mortality which proves the oncologic world doesn’t know their own literature. What level of progesterone is best for breast cancer protection and what level of testosterone is most appropriate? All hormones have been demonstrated to protect against cancer and it is the loss of hormones that increases that risk. Only one hormone increases cancer risk and that is a drug and not a hormone. It is amazing what medical experts do not know or understand about hormones and will make incorrect assumptions to avoid HRT whereas doing so increases morbidity and mortality. They cause harm by not utilizing HRT but they don’t understand that they don’t know.
12:15 – 1:15 p.m. Lunch Break
1:15 – 2:15 p.m.
Section 2 Continued
2:15 – 3:15 p.m.
Interesting articles and facts on HRT: A literature review of what the experts don’t tell you about risks and benefits of HRT. Don’t ignore the world’s literature-the WHI does not negate all prior studies. Become conversant in all the other studies in opposition to WHI. Don’t assume or extrapolate the harm of CEE/MPA to E2/P4. It is amazing what medical experts do not know or understand about hormones and will make incorrect assumptions to avoid HRT whereas doing so increases morbidity and mortality. They cause harm by not utilizing HRT, but they don’t realize that they truly don’t know or understand hormones. Literature review of HRT, new and most recent that was not covered in Part I. Everyday there is something new and this is the venue that keeps us up to date.
3:15 – 3:30 p.m. Break
3:30 – 5:30 p.m.
Testosterone’s risks and benefits from JCEM and NEJM meta-analysis, new guidelines, and alternative methods of prescribing testosterone for men and women. Learn all the alternative methods of raising testosterone levels besides transdermal creams. When to avoid transdermal, when to avoid IM, when to use HCG vs. clomiphene, and when to use oral testosterone? Which are the cheapest, which are the best, and which ones should be avoided. Basically, everything you could possibly ever need to know about optimizing testosterone. A literature review (EBM) will support the many alternative methods to raising testosterone.
5:30 – 6:00 p.m.
Question and Answer
8:00 – 10:00 a.m.
A literature review of the battle and controversy over oral vs. transdermal estrogen, which type, how, when, why, and how the ESTHER study guides us. Knowledge is power when it comes to estrogen administration, the risks and benefits of both. Review of HRT and clotting and how to evaluate the risk and decrease the risk. And just what is that relative risk anyway that everyone always alludes to? Please don’t tell me the risk of clotting-rather give me the numbers. The importance of SHBG in prescribing E2 as it pertains to CA and CAD. Thrombophilia work-up, test panels with case examples of + labs and how patients should be treated. Develop a treatment plan that encompasses the foregoing but that requires in-depth knowledge of the vast literature and relative risks. Finally, OK, what to do when someone develops a clot while on HRT and has a negative work-up, or that has had a prior clot, even if provoked. Review the harm of transdermal estradiol and the null set.
10:00 – 10:15 Break
10:15 – 11:15 a.m.
Thyroid update and cardiovascular review articles of the importance of T3 optimization for cardiac disease prevention and lipid improvements. Thyroid replacement does not cause osteoporosis- an extensive literature review. So, you think you know thyroid? More cases, labs, and articles. More literature support for optimizing T3 in spite of AACE recommendations to the contrary. U.S. Pharmacopeia report on desiccated thyroid. Stock up now because desiccated thyroid is going away thanks to big Pharma.
11:15 – 12:15 p.m.
Preventive cardiology or how to avoid CABG, stents, and MI when statins don’t work: A literature review of hormones, toxic blood markers, prediction of CVD, and treatment without using common CVD drugs that don’t always work. Preferential use of hormones, EFA, supplements, life style changes, and diet to prevent CVD and how to monitor effects via the NMR panel. The expert recommendations are to no longer monitory cholesterol levels, as LDL may not predict CAD, but HDL does. Then what should we monitor and what is predictive? LDL particle number and small LDL particle numbers. We’ll look at the cases and outcomes.
12:15 – 1:15 p.m. Lunch Break
1:15 – 2:15 p.m.
Cardiology cases: How to stop progression of the disease. Management when statins don’t lower LDL-P and small LDL-P. That which the cardiologists should use but don’t. Putting all the pieces together using the best preventive strategies to avoid succumbing to that which kills 90% of us. Use of NMR panel, LDL-P’s, apo-B, non-HDL cholesterol, cardiac markers, insulin, and inflammatory cytokines. Does lowering cholesterol by means other than statins provide the same benefits? Lowering LDL is just a small piece of the pie. What can be/should be offered in addition to statins?
2:15 – 3:15 p.m.
Complex cases, labs, adjustments, fun and interesting cases, and lots of WWND (What Would Neal Do) cases. Lab updates that utilize the new reagents with comparisons with the old labs and reagents. Conversion to the new reference ranges.
3:15 – 3:30 p.m. Break
3:30 – 5:30 p.m.
Questions and Answer case studies
5:30 – 6:00 pm
Questions and Answer with Group
8:00 – 10:00 a.m.
Polycystic Ovary Syndrome: Diagnosis and treatment of the most common pre-menopausal endocrinopathy that everyone fails to diagnosis. Never miss it again because if you don’t specifically look for it, then you won’t find it. PCOS increases risk of CAD, DM, breast cancer, & uterine cancer which further emphasizes the need for early detection and treatment. Assume that everyone has PCOS until you prove that they don’t. Unfortunately the most common treatments for PCOS don’t work. There is only one treatment that will work and that is the one that no one knows or appreciates. We’ll review the before and after labs demonstrating improvement. Quality of life and fertility relies on this one treatment.
10:00 – 10:15 a.m. Break
10:15 – 11:15 a.m.
Osteoporosis: Diagnosis and treatment using DEXA scan and NTX urine metabolites to monitor bone loss. Treatment of osteoporosis beyond bisphosphonates: HRT, Vitamin D, Vitamin K, strontium, ipraflavone. Measuring and monitoring improvements in NTX- a lab review.
Estrogen metabolites- do they or do they not predict breast cancer and should we waste money on testing. Lab review of 2 OH-E1 vs. 16α OH-E1. DIM? Do you really need it and does it really work? I didn’t know that estradiol caused cancer, so why use DIM? A look at EBM and studies from JNCI that refute confabulation.
11:15 – 12:15 a.m.
Estrogen and Progesterone in men: What the literature supports in so far as harmful effects of low vs. high levels. Use of aromatase inhibitors in men or how to increase the risk of CAD, CVD, dementia, osteoporosis, and ED by blocking estrogen. The harm of prescribing progesterone in men unless you want to increase the risk of MI or ED and inflammation. Use EBM to guide your therapy, not what someone theorizes.
Review of the chronic fatigue syndrome: Treatment by optimizing T3. The use of cortisol for symptomatic relief of CFS: A literature review. Cortisol: Prescribing, monitoring, adjusting, and use of ACTH stimulation test. Addison’s disease vs. adrenal insufficiency vs. adrenal suppression and the use of ACTH stimulation test for diagnosis and tapering. Just what is adrenal fatigue and how to diagnosis via saliva testing even when the serum cortisol level is normal?
12:15 p.m. Adjourn
AMA PRA Category 1 Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Foundation for Care Management (FCM) and Worldlink Medical. The Foundation for Care Management is accredited by the ACCME to provide continuing medical education for physicians.
FCM designates this educational activity for a maximum of 21 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in this activity.
The ACCME defines a “Commercial Interest” as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.
Foundation for Care Management is accredited as a provider of nursing continuing professional development
by the American Nurses Credentialing Center’s Commission on Accreditation.
The Foundation for Care Management is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Program # 0347-9999-20-002-L01-P Objectives appropriate for pharmacists. This activity is 21 Contact Hours Pharmacy Credit. *This CME is Knowledge Based (K). Initial release April 3, 2020
- The Foundation for Care Management cannot provide a statement of credit unless an evaluation form has been filled out online. Please go to fcmcme.org to access the evaluation form.
Location & Travel Details